Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

Urology

Volumn 53, Issue 3, 1999, Pages 581-589

  Roehrborn, Claus G ^a   Boyle, Peter ^b   Gould, A Lawrence ^c   Waldstreicher, Joanne ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORGAN SIZE; PREDICTION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; UROLOGIC EXAMINATION;

ADULT; AGED; CLINICAL TRIALS; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; SENSITIVITY AND SPECIFICITY;

EID: 0033104455     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00655-4     Document Type: Article

References (26)

1. Berry S.J., Coffey D.S., Walsh P.C., et al. The development of human benign prostatic hyperplasia with age. J Urol. 132:1984;474-479.
2. Bosch J.L., Hop W.C., Niemer A.Q., et al. Parameters of prostate volume and shape in a community based population of men 55 to 74 years old. J Urol. 152:(5 Pt 1):1994;1501-1505.
3. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men. JAMA. 270:1993;860-864.
4. Oesterling J.E., Kumamoto Y., Tsukamoto T., et al. Serum prostate-specific antigen in a community-based population of healthy Japanese men lower values than for similarly aged white men . Br J Urol. 75:1995;347-353.
5. Rhodes T., Girman C.J., Jacobsen S.J., et al. Longitudinal measures of prostate volume in a community-based sample 3.5 year followup in the Olmsted County study of health status and urinary symptoms among men . J Urol. 153:1995;301A.
6. Bonilla J., Roehrborn C.G., McConnell J.D., et al. Patterns of prostate growth observed in placebo treated patients in the PLESS trial over four years (abstract). J Urol. 159:(5 suppl):1998;333.
7. Lepor H., Williford W.O., Barry M.J., et al. A randomized placebo controlled clinical trial of the safety and efficacy of therapies in men with clinical benign prostatic hyperplasia. N Engl J Med. 335:1996;533-539.
8. Roehrborn CG, Oesterling JE, Olson PJ, et al, for the HYCAT Investigator Group . Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. Urology. 50:1997;556-561.
9. Benson M.C., Whang I.S., Pantuck A., et al. Prostate specific antigen density a means of distinguishing benign prostatic hypertrophy and prostate cancer . J Urol. 147:1992;815-816.
10. Benson M.C., Whang I.S., Olsson C.A., et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 147:1992;817-821.
11. Bosch J.L., Hop W.C., Bangma C.H., et al. Prostate specific antigen in a community-based sample of men without prostate cancer correlations with prostate volume, age, body mass index, and symptoms of prostatism . Prostate. 27:1995;241-249.
12. Aarnink R.G., de la Rosette J.J., Huynen A.L., et al. Standardized assessment to enhance the diagnostic value of prostate volume. Part II: correlation with prostate-specific antigen levels . Prostate. 29:1996;327-333.
13. Yu H.J., Chiang G.J., Chiu T.Y., et al. Relationship between serum prostate specific antigen concentration and prostate volume. J Formosan Med Assoc. 94:1995;666-670.
14. Di Silverio F., Sciarra A., D'Eramo G., et al. Relationship among age, prostate-specific antigen, and prostate volume in men with lower urinary tract symptoms (LUTS) and in different groups of men with and without benign and malignant prostate diseases. Prostate. 36:1998;1-7.
15. Jacobsen S.J., Jacobson D.J., Girman C.J., et al. Natural history of prostatism risk factors for acute urinary retention . J Urol. 158:1997;481-487.
16. Roehrborn CG, McConnell JD, Lieber M, et al, for the PLESS Study Group . Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology. 53:1999;473-480.
17. Boyle P., Gould A.L., Roehrborn C.G. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride meta-analysis of randomized clinical trials . Urology. 48:1996;398-405.
18. Roehrborn C.G., Girman C.J., Rhodes T., et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology. 49:1997;548-557.
19. Gormley GJ, Stoner E, Bruskewitz RC, et al, for the Finasteride Study Group . The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1992;1185-1191.
20. Andersen JT, Ekman P, Wolf H, et al, for the Scandinavian BPH Study Group . Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology. 46:1995;631-637.
21. Nickel J.C., Fradet Y., Boake R.C., et al. Efficiacy and safety of finasteride therapy for benign prostatic hyperplasia results of a 2-year randomized controlled trial (the PROSPECT Study) . Can Med Assoc J. 155:1996;1251-1259.
22. Bonilla J., Stoner E., Grino P., et al. Intra- and interobserver variability of MRI prostate volume measurements. Prostate. 31:1997;98-102.
23. McConnell JD, Bruskewitz R, Walsh P, et al, for the Finasteride Long-Term Efficacy and Safety Study Group . The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 338:1998;557-563.
24. Marberger MJ, for the PROWESS Study Group . Long-term effects of finasteride in patients with benign prostatic hyperplasia a double-blind, placebo-controlled, multicenter study . Urology. 51:1998;677-686.
25. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. The establishment of age specific reference ranges for prostate specific antigen. J Urol. 149:1993;510A.
26. Girman C.J., Jacobsen S.J., Guess H.A., et al. Natural history of prostatism relationship among symptoms, prostate volume and peak urinary flow rate . J Urol. 153:1995;1510-1515.